Upfront low-dose ponatinib (15 mg/day) for multi-TKI resistant chronic myeloid leukemia

Research output: Contribution to journalLetter

4 Citations (Scopus)
Original languageEnglish (US)
Pages (from-to)718-720
Number of pages3
JournalHematological Oncology
Volume36
Issue number4
DOIs
StatePublished - Oct 1 2018

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
ponatinib

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Upfront low-dose ponatinib (15 mg/day) for multi-TKI resistant chronic myeloid leukemia. / Tefferi, Ayalew.

In: Hematological Oncology, Vol. 36, No. 4, 01.10.2018, p. 718-720.

Research output: Contribution to journalLetter

@article{c845d712e73f4eb5a9a7ccac04652670,
title = "Upfront low-dose ponatinib (15 mg/day) for multi-TKI resistant chronic myeloid leukemia",
author = "Ayalew Tefferi",
year = "2018",
month = "10",
day = "1",
doi = "10.1002/hon.2517",
language = "English (US)",
volume = "36",
pages = "718--720",
journal = "Hematological Oncology",
issn = "0278-0232",
publisher = "John Wiley and Sons Ltd",
number = "4",

}

TY - JOUR

T1 - Upfront low-dose ponatinib (15 mg/day) for multi-TKI resistant chronic myeloid leukemia

AU - Tefferi, Ayalew

PY - 2018/10/1

Y1 - 2018/10/1

UR - http://www.scopus.com/inward/record.url?scp=85054818562&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054818562&partnerID=8YFLogxK

U2 - 10.1002/hon.2517

DO - 10.1002/hon.2517

M3 - Letter

C2 - 29901221

AN - SCOPUS:85054818562

VL - 36

SP - 718

EP - 720

JO - Hematological Oncology

JF - Hematological Oncology

SN - 0278-0232

IS - 4

ER -